Lysophosphatidylcholine binds α-synuclein and prevents its pathological aggregation

Area of Science:

• Neuroscience
• Biochemistry
• Genetics

Background:

• Parkinson's disease (PD) is characterized by aggregated alpha-synuclein (α-syn) in Lewy bodies.
• Genetic links between lipid metabolism and Parkinsonism highlight the importance of lipids in PD pathogenesis.
• The precise lipids influencing α-syn aggregation and neurodegeneration are not fully understood.

Purpose of the Study:

• To investigate the specific lipid interactions with α-synuclein (α-syn).
• To determine the role of lysophospholipids (LPLs) in modulating α-syn aggregation.
• To explore the connection between lipid metabolism dysfunction and PD pathology.

Main Methods:

• Investigated α-syn binding preferences using various lipids.
• Assessed the effect of lysophosphatidylcholine (LPC) on α-syn conformation and aggregation in vitro and in cells.
• Correlated cellular LPL levels with α-syn accumulation.

Main Results:

• α-syn preferentially binds to lysophospholipids (LPLs), particularly lysophosphatidylcholine (LPC).
• LPC binding maintains α-syn in a compact, non-aggregating conformation.
• Reduced cellular LPL production correlates with increased α-syn aggregation.

Conclusions:

• LPLs, especially LPC, play a crucial role in inhibiting α-syn aggregation by stabilizing its native conformation.
• Dysfunctional lipid metabolism, leading to reduced LPLs, may contribute to α-syn accumulation and Parkinson's disease.
• Targeting LPLs could offer a novel therapeutic strategy for PD.